To determine the correlation of CD4+CD28null T cells with MS progression, we first assessed whether the presence of these cells is associated with higher disease severity using Kurtzke expanded disability status scale (EDSS) and multimodal evoked potentials (EP) as outcome measures. This evidence concerns the gene CD4 and myeloid sarcoma.